Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis. In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
- Target Recruit Count
- 40
- Registration Number
- NCT02694224
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
- Conditions
- Skin Basal Cell Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Anne Chang
- Target Recruit Count
- 16
- Registration Number
- NCT02690948
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT02674009
- Locations
- 🇩🇪
Klinik Johann Wolfgang von Goethe Uni; Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany
Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 55
- Registration Number
- NCT02667574
- Locations
- 🇫🇷
CHU Ambroise Paré, Paris, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷CH de Boulogne sur mer, Boulogne sur mer, France
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT02648048
- Locations
- 🇺🇸
Tulane University Medical School, New Orleans, Louisiana, United States
🇺🇸Suburban Lung Associates, Elk Grove, Illinois, United States
🇺🇸Allied Clinical Research, Reno, Nevada, United States
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 4
- Registration Number
- NCT02639117
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT02593760
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
🇺🇸Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial CarcinomaEsophageal CarcinomaExocrine Pancreas Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Cytology Specimen Collection ProcedureProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanProcedure: Echocardiography TestOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02436408
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.